Vardenafil (Levitra/Staxyn) Medicare Part D Coverage

Why Medicare Part D Usually Excludes Vardenafil

Most Medicare Part D plans do not cover vardenafil because federal law gives plan sponsors the option to exclude drugs used for erectile dysfunction (ED) from their formularies. The Medicare Modernization Act of 2003 placed ED medications in a category of "drugs that may be excluded from coverage," alongside drugs for weight loss, cosmetic purposes, and fertility [1]. The Centers for Medicare & Medicaid Services (CMS) has maintained this classification in subsequent guidance, meaning Part D sponsors face no penalty for omitting PDE5 inhibitors from their drug lists [2].

A 2005 CMS memorandum clarified that Part D sponsors could choose to cover ED drugs but were not obligated to do so [2]. In practice, the overwhelming majority of plans opt out. An analysis of Part D formulary data from CMS showed that fewer than 5% of standalone prescription drug plans listed any PDE5 inhibitor on formulary during the 2024 plan year [3]. For enrollees who do find a plan covering vardenafil, access usually requires prior authorization and a confirmed diagnosis of ED secondary to a covered medical condition such as radical prostatectomy or spinal cord injury. Even then, quantity limits of 6 to 8 tablets per month are standard [3].

The practical result is straightforward: if you are a Medicare beneficiary seeking vardenafil, you will almost certainly pay the full retail price. Understanding this exclusion is the first step toward identifying real savings strategies.

Generic Vardenafil vs. Brand Levitra and Staxyn

Bayer's brand-name Levitra (vardenafil hydrochloride tablets) has been effectively discontinued in the U.S. market, though authorized generics entered the market after FDA approval of abbreviated new drug applications beginning in 2018 [4]. Staxyn, the orally disintegrating tablet formulation, remains available but carries a higher price point and no generic equivalent as of mid-2026. The FDA originally approved vardenafil in August 2003 based on key trials demonstrating statistically significant improvements in the International Index of Erectile Function (IIEF) erectile function domain score compared to placebo [5].

Generic vardenafil tablets (available in 5 mg, 10 mg, and 20 mg strengths) now account for the majority of U.S. prescriptions. Cash prices vary widely by pharmacy. National averages from GoodRx as of May 2026 show generic vardenafil 20 mg ranging from $8 per tablet at cost-leaders like Costco to $65 per tablet at chain pharmacies without a discount coupon [6]. The FDA's Orange Book confirms therapeutic equivalence (AB rating) between approved generics and the original Levitra NDA, meaning bioequivalence has been demonstrated in pharmacokinetic studies [4].

Staxyn (vardenafil ODT 10 mg) uses a different salt form (vardenafil monohydrochloride trihydrate) and is not interchangeable with standard vardenafil tablets. The ODT formulation provides faster oral absorption in some patients, but head-to-head efficacy data comparing the two formulations remain limited [7]. Because Staxyn has no generic, its cash price typically exceeds $50 per tablet at retail.

What Vardenafil Costs Without Insurance in 2026

Without any insurance coverage, a Medicare enrollee filling a prescription for generic vardenafil will face the full retail cost. A 2023 JAMA Internal Medicine study found that out-of-pocket spending on ED medications increased by 16% among Medicare beneficiaries between 2012 and 2020, largely because of the Part D exclusion [8]. That trend has continued.

Here is what to expect in 2026. Generic vardenafil 20 mg, 10 tablets: $80 to $200 at chain pharmacies without a discount card. The same quantity drops to $30 to $90 with GoodRx, RxSaver, or a similar coupon aggregator [6]. Costco and Mark Cuban's Cost Plus Drugs pharmacy tend to offer the lowest per-tablet prices, sometimes below $4 per tablet for generic vardenafil [9].

Brand Staxyn carries a higher burden. Ten tablets of Staxyn 10 mg ODT can cost $400 to $600 without a coupon. No manufacturer coupon program is currently active for Staxyn following changes to Bayer's patient support initiatives [10].

For comparison, generic sildenafil (Viagra's equivalent) often costs $1 to $3 per tablet at discount pharmacies, and generic tadalafil (Cialis's equivalent) runs $1 to $5 per tablet [6]. These price differences explain why many prescribers default to sildenafil or tadalafil as first-line therapy. The American Urological Association (AUA) guidelines classify all PDE5 inhibitors as first-line pharmacotherapy for ED, leaving the choice between agents to patient preference, side-effect profile, and cost [11].

How to Reduce Your Vardenafil Costs on Medicare

Several strategies can lower the financial burden for Medicare enrollees paying cash for vardenafil.

Prescription discount cards and coupon aggregators. Sites such as GoodRx, RxSaver, and SingleCare negotiate contracted rates with retail pharmacies. These coupons are not insurance. They simply apply a pre-negotiated discount at the pharmacy counter. For generic vardenafil, savings of 40% to 80% off the retail price are common [6]. You can use these coupons even if you have a Part D plan, provided you are paying cash (not submitting a Part D claim) for the prescription.

Pill splitting. The AUA and clinical pharmacology references note that vardenafil tablets are scored and can be split [11]. A 20 mg tablet split in half yields two 10 mg doses. If your prescribed dose is 10 mg, buying 20 mg tablets and splitting them can cut your per-dose cost by roughly 50%. Discuss this approach with your prescriber first.

Patient assistance programs (PAPs). Bayer's patient assistance program for Levitra has been discontinued. Generic manufacturers such as Teva and Aurobindo do not typically offer PAPs for vardenafil specifically. The NeedyMeds database and Medicare's Extra Help (Low-Income Subsidy) program may provide indirect assistance for qualifying beneficiaries [12]. Extra Help can reduce Part D premiums, deductibles, and copays, but only for drugs that are on the plan's formulary, which typically excludes ED medications [2].

State pharmaceutical assistance programs (SPAPs). Approximately 23 states operate SPAPs that supplement Medicare Part D. Coverage of ED drugs varies by state. New York's EPIC program, for example, has historically excluded ED medications, while some smaller programs have covered them on a limited basis [13]. Check your state's program before assuming exclusion.

Telehealth and direct-to-patient pharmacies. Platforms such as HealthRX offer prescriber consultations and generic or compounded ED medications shipped directly to your door, often at prices well below retail. Compounded vardenafil, prepared by a 503B outsourcing facility registered with the FDA, may cost less than $5 per dose in some cases [14]. The FDA regulates 503B outsourcing facilities under Section 503B of the Federal Food, Drug, and Cosmetic Act, requiring current good manufacturing practice (cGMP) compliance [14].

Clinical Profile: How Vardenafil Compares to Other PDE5 Inhibitors

Understanding where vardenafil fits among PDE5 inhibitors can help Medicare enrollees make informed cost-versus-benefit decisions. All four FDA-approved PDE5 inhibitors (sildenafil, tadalafil, vardenafil, and avanafil) work by inhibiting the PDE5 enzyme in corpus cavernosum smooth muscle, increasing cyclic guanosine monophosphate (cGMP) levels, and facilitating penile erection in the presence of sexual stimulation [5].

Vardenafil's time to onset is approximately 30 to 60 minutes, with a duration of action around 4 to 5 hours. Tadalafil's duration extends to 36 hours, giving it an advantage for patients who prefer spontaneity. A meta-analysis published in the Journal of Sexual Medicine comparing PDE5 inhibitor efficacy across 82 randomized controlled trials (N = 47,626) found no statistically significant difference in IIEF erectile function domain improvement among the four agents at their recommended starting doses [15]. Differences in side-effect profiles, drug interactions, and half-life drive the clinical choice more than raw efficacy.

Vardenafil carries a specific warning regarding QT prolongation. The FDA label notes that vardenafil 10 mg produced a mean QTc increase of 8 ms in a thorough QT study, and the 80 mg supratherapeutic dose extended QTc by 10 ms [5]. Patients taking Class IA or Class III antiarrhythmics (quinidine, procainamide, amiodarone, sotalol) should avoid vardenafil. The drug is also contraindicated with nitrates and alpha-blockers at specific doses, consistent with all PDE5 inhibitors [16].

For Medicare enrollees already taking multiple medications, a pharmacist-led medication therapy management (MTM) review, which Medicare Part D plans are required to offer to qualifying complex patients, can help identify potential interactions [17]. The MTM review itself is covered by Part D even though the ED drug is not.

Medicare Advantage Plans: A Possible Alternative

Some Medicare Advantage (Part C) plans offer supplemental benefits that include limited ED drug coverage. These plans bundle Part A, Part B, and usually Part D together and may add extras like dental, vision, and prescription drug benefits beyond the standard Part D formulary [18]. A small number of Medicare Advantage plans have begun offering a fixed monthly allowance (for example, $50 to $100 per month) for drugs in excluded Part D categories, including ED medications.

Enrollment in a Medicare Advantage plan with this supplemental benefit requires careful comparison during the Annual Enrollment Period (October 15 to December 7). The Medicare Plan Finder tool on Medicare.gov allows beneficiaries to search formularies by drug name and compare out-of-pocket costs across plans [3]. Type "vardenafil" in the drug search to see which plans in your ZIP code include any coverage. Even when listed, expect tier 3 (preferred brand) or tier 4 (non-preferred) placement with copays of $40 to $75 per fill [3].

The Inflation Reduction Act of 2022 capped total Part D out-of-pocket spending at $2,000 per year starting in 2025 [19]. This cap applies only to drugs covered by the Part D formulary. Because ED drugs are excluded from most formularies, cash payments for vardenafil will not count toward this cap, and the $2,000 ceiling will not protect you from ongoing ED drug expenses.

Veterans and TRICARE: Different Rules Apply

Veterans enrolled in the VA healthcare system may access vardenafil through the VA formulary, which operates independently of Medicare Part D. The VA National Formulary has historically included at least one PDE5 inhibitor, typically sildenafil, with vardenafil or tadalafil available through non-formulary request if sildenafil is ineffective or contraindicated [20]. Co-pays for VA prescriptions are tiered at $5 for preferred generics and $11 for non-preferred drugs for Priority Group 2-8 veterans, which is substantially lower than retail prices [20].

TRICARE (the military health plan for active duty, retirees, and dependents) covers generic vardenafil on its formulary with prior authorization. A diagnosis of ED and documentation of at least one failed conservative treatment are typically required. TRICARE copays for generic vardenafil at a retail pharmacy run approximately $14 for a 30-day supply under the Select plan [21].

When to Talk to Your Doctor About Switching

If cost is the primary barrier to continuing vardenafil, your prescriber may recommend switching to generic sildenafil or tadalafil, both of which are available for under $3 per tablet at discount pharmacies. A Cochrane systematic review of PDE5 inhibitors for ED confirmed comparable efficacy across agents, though individual response and tolerability vary [22]. Daily low-dose tadalafil (2.5 mg or 5 mg) is the only PDE5 inhibitor FDA-approved for both ED and benign prostatic hyperplasia (BPH) symptoms, which may provide added value for men with both conditions [23].

If you have tried and failed sildenafil and tadalafil, or if you experience specific side effects (tadalafil-associated back pain occurs in approximately 6% of patients; sildenafil-related visual disturbances affect about 3%), vardenafil remains a clinically valid alternative [15]. Document these treatment failures. A written record may support a formulary exception request or prior authorization appeal if you identify a Part D or Medicare Advantage plan that offers any ED drug coverage.

For Medicare enrollees spending more than $50 per month on ED medication, a telehealth consultation through HealthRX can identify the most cost-effective PDE5 inhibitor option, including compounded formulations, and coordinate prescription transfer to a lower-cost pharmacy.